Background: In multiple sclerosis, development of screening tools for remyelination-promoting molecules is timely. Objective: A Xenopus transgenic line allowing conditional ablation of myelinating oligodendrocytes has been adapted for in vivo screening of remyelination-favoring molecules. Methods: In this transgenic, the green fluorescent protein reporter is fused to E. coli nitroreductase and expressed specifically in myelinating oligodendrocytes. Nitroreductase converts the innocuous pro-drug metronidazole to a cytotoxin. Spontaneous remyelination occurs after metronidazole-induced demyelinating responses. As tadpoles are transparent, these events can be monitored in vivo and quantified. At the end of metronidazole-induced demyelination, tadpoles were screened in water containing the compounds tested. After 72 h, remyelination was assayed by counting numbers of oligodendrocytes per optic nerve. Results: Among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination. Crispr/cas9 gene editing showed that the promyelinating effect of siponimod involves the sphingosine-1-phosphate receptor 5. Conclusion: This Xenopus transgenic line constitutes a simple in vivo screening platform for myelin repair therapeutics. We validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.
Introduction
Oligodendrocytes are the myelin-forming cells of the central nervous system (CNS). During embryonic development, cells of the oligodendrocyte lineage emerge from the ventricular zone. Successive developmental stages transform the neural stem cells into proliferating oligodendrocyte progenitors, which migrate into the parenchyma as oligodendrocyte precursor cells (OPCs) before differentiating, successively into a pre-oligodendrocyte, then a mature postmitotic oligodendrocyte, and finally a myelinforming oligodendrocyte. These developmental stages, which are associated with different capacities of proliferation, migration, differentiation, survival, maturation, and finally myelin deposition, are cell autonomous, but also depend on a variety of extrinsic factors.
In multiple sclerosis (MS), remyelination often fails despite OPC presence around demyelinating areas. 1 Repair of demyelinated lesions could enhance successful re-ensheathing of naked axons by oligodendrocyte processes. Existing MS models (mostly rodent and primates) are not ideal for monitoring in vivo demyelination and remyelination, hence the need to develop simpler strategies for larger scale screening of compounds favoring myelin repair. 2 We developed a transgenic Xenopus laevis permitting live imaging of demyelination and remyelination by conditionally triggering apoptotic ablation of myelin-forming oligodendrocytes. 3 This line, MBP-GFP-NTR, expresses green fluorescent protein (GFP) fused to E. coli nitroreductase (NTR) under control of the mouse 1.9 kb myelin basic protein (MBP) regulatory sequence. In the mouse, this portion of the proximal upstream region of MBP gene drives reporter expression specifically in myelinating oligodendrocytes. 4 Like the mouse, the transgenic MBP-GFP-NTR X. laevis expresses the GFP-NTR transgene specifically in myelin-forming oligodendrocytes.
The NTR enzyme converts the nitro radical of prodrugs, including metronidazole, to a highly cytotoxic hydroxylamine derivative. In metronidazole-exposed transgenic MBP-GFP-NTR tadpoles, demyelination is restricted to the CNS, without axonal damage. 3 The extent of demyelination depends on the concentration and duration of metronidazole exposure. Spontaneous remyelination occurs and is nearly complete 8 days after cessation of metronidazole. As embryos are transparent, demyelination and remyelination can be monitored and quantified in vivo under a fluorescent macroscope. 3 We used this model to screen molecules favoring remyelination.
Among the battery of molecules tested, one of the most potent agonist to accelerate remyelination was siponimod, which was recently evaluated in a Phase III trial in secondary-progressive MS. 5 Siponimod is a dual agonist of sphingosine-1-phosphate (S1P) receptors, S1PR1 and S1PR5. S1P has been identified as the endogenous ligand of the five known S1P receptors (S1PR1, S1PR2, S1PR3, S1PR4, and S1PR5), a family of G-protein coupled receptors. 6 In the rodent CNS, the S1PR5 receptor is expressed only by cells of the oligodendroglial lineage and its activation is important in the oligodendrocyte maturation. It was therefore suggested that S1PR5 may play a key role in myelin sheath repair. 7 Here, we questioned whether the remyelinating effect of siponimod implicated S1PR5. We show that, in tadpoles with Crispr/Cas 9 gene deleted S1PR5, siponimod no longer promotes remyelination. Another S1PR5 agonist (UC-42-WP04) also favored remyelination, while an S1PR1 agonist (AUY954) had no effect. The data provide strong evidence that siponimod-stimulated remyelination implicates S1PR5 activation and illustrate that MBP-GFP-NTR Xenopus is an efficient and simple experimental model to screen molecules favoring remyelination. Immunostaining of clarified samples CLARITY-processed brains were incubated in blocking solution overnight at 4°C. Samples were further incubated in staining solution with primary antibodies (anti-GFP) for 7 days at room temperature with under gentle agitation. After two washes with phosphatebuffered saline containing 0.1% Tween-20 (PBT), samples were incubated in a staining solution with secondary antibody for 7 days at room temperature. Samples were subsequently washed for 48 hours in PBT.
Materials and methods

Animals
Immunolabeling on tissue sections
Tadpoles were fixed by immersion in 4% paraformaldehyde and treated for immunostaining as described. 3 Electron microscopy (EM) and morphometry are detailed in the Supplementary Materials.
Metronidazole preparation and use
Metronidazole (10 mM, Fluka) was dissolved in filtered tap water containing 0.1% dimethyl sulfoxide (DMSO) (Sigma Aldrich) and added to aquaria water for 10 days.
Tadpoles were maintained in 600 mL of metronidazole solution (maximum 10 tadpoles/600 mL) at 23.5°C in complete darkness (metronidazole is light-sensitive) and changed every 72 hours throughout treatment. For regeneration experiments, metronidazole-treated animals were allowed to recover for up to 8 days in either normal water or containing compounds to be tested at different concentrations in ambient laboratory lighting (12-hour light 12-hour dark).
Quantification of GFP+ cells GFP was detected directly by fluorescence in live embryos using an AZ100 Nikon Zoom Macroscope. In the optic nerve, the total number of GFP+ cells was counted, from the emergence of the nerve (i.e. after the chiasm) to the retinal end before and after metronidazole treatment and after treatment with the compound to be tested on the same embryos. Double-blind counts were performed independently by two researchers. Data were compared to control untreated animals of the same developmental stage. Data presented are the mean ± standard error of the mean (SEM) of number of GFP+ cells counted on at least six tadpoles per condition. Preparation of single guide RNAs (sgRNAs), generation of S1P5 null mutant, and polymerase chain reaction (PCR) primers are described in the Supplementary Materials.
Statistical analysis
Prism v5 software was used for statistical analyses. Results are expressed as means ± SEM. To assess differences between more than two groups when comparing efficiency of remyelinating drugs, parametric two-way analysis of variance (ANOVA) was used (after normality test passed using ShapiroWilk normality test) followed by an uncorrected Fisher's least significant difference (LSD) test.
Other p values for comparison of means are from Student's two-tailed t-tests. Analysis of covariance was used to analyze regression lines. Statistical significance was set at p < 0.05. Significant differences are indicated by asterisks: *p < 0.05, **p < 0.01, and ***p < 0.001. 
Results
Oligodendrocyte visualization in MBP-GFP-NTR
Conditional ablation and spontaneous repair in the MBP-GFP-NTR Xenopus tadpole
Stage NF52-53 MBP-GFP-NTR transgenic X. laevis were treated with metronidazole (10 mM) introduced in the aquarium water to induce conditional demyelination. Screening experiments focused on the embryonic optic nerve, easily monitored by live imaging. The number of GFP+ oligodendrocytes is moreover small and very reproducible at each developmental stage, facilitating quantification. After 10 days of metronidazole, the number of GFP+ cells per optic nerve significantly decreased from 13.9 ± 1.0 to 2.3 ± 2 (p < 0.01) (Figure 1(d) , upper panel). The extent of demyelination was further investigated using EM showing the depletion of myelin around axons, and the presence of myelin debris (Supplementary Figure S2A, B) . After 10 days of metronidazole exposure, tadpoles were returned to normal water and recovery occurred rapidly: oligodendrocytes per optic nerve reached 8.3 ± 0.9 and 13.3 ± 1.5 at R3 and R8, respectively (Figure 1(d) , lower panel). Of note, during the 10 days of metronidazole treatment at 23°C, tadpoles progress from stage 52 to stage 55 (see http://www.xenbase.org/ anatomy/alldev.do); therefore, during the recovery period, not only demyelinated axons undergo remyelination, but it is likely that in addition some previously naked axons are also myelinated.
Transgenic MBP-GFP-NTR Xenopus tadpoles as a screening platform for molecules enhancing remyelination
We reasoned that our model could serve for screening potential remyelination-favoring molecules by quantifying remyelination rates as a function of increases in GFP+ cell numbers following demyelination. Since spontaneous repair was often complete at R8, we chose to evaluate repair efficiency only at R3, that is, 3 days after metronidazole removal. We compared the promyelinating effect of 20 compounds for which an effect on myelination (or remyelination) has been described (Table 1 ). Among the molecules tested, the three most efficient were, by increasing order, as follows: siponimod (3 nM), UC-42-WP04 (10 nM), and clemastine (100 nM) (Figure 2 ). It is noteworthy that UC-42-WP04, a selective S1PR5 agonist, 11 was among the most efficient remyelinating drugs, while AUY954, a selective S1PR1 agonist, 12 had no effect. Since siponimod is a dual S1P1 and S1P5 receptor agonist, we investigated further siponimod's remyelinating potential.
Xenopus oligodendrocytes express S1P5 receptor As oligodendrocytes in the mouse brain selectively express S1PR5, 7 we questioned whether S1PR5 expression was also restricted to oligodendrocytes in X. laevis. We investigated oligodendroglial expression of S1PR5 in X. laevis by triple immunolabeling of brain stem tissue sections of MBP-GFP-NTR tadpoles (stages 52-53) using a rabbit anti-S1PR5 antibody, a chicken anti-GFP to label mature oligodendrocyte, and a goat anti-Sox-10 to label all cells from the oligodendroglial lineage. We observed a perfect cellular colocalization of Sox10 and S1PR5 (21.5 ± 6.5 cells/ mm 2 ) and all the GFP+ cells were S1P5+ (14.5 ± 5.3 GFP+/S1PR5+ cells/mm 2 ). Since, in the CNS, Sox10 is an established marker of the oligodendroglial lineage, we concluded that the S1P5+/Sox10+/GFP− cells are most likely OPCs. Altogether our data suggest that in the Xenopus CNS, as in the mouse, S1P5 expression is restricted to the oligodendrocyte lineage and that all myelin-forming oligodendrocytes (GFP+ cells) express S1PR5 ( Figure 3) .
Detection of myelinated fibers following siponimod treatment
To verify that increased numbers of myelinating oligodendrocytes translated into increased myelination, brain stem tissue sections were immunolabeled with anti-MBP, an established myelin marker. Transgenic MBP-GFP-NTR X. laevis (n = 18) (stages 52-53) were treated for 10 days with metronidazole (n = 15), then returned to normal water (n = 3) or water containing siponimod (3 nM) for either 3 days (n = 3) or 8 days (n = 3) prior to MBP immunostaining ( Figure 4 ). After 10 days of metronidazole treatment, a nearly complete demyelination was achieved (compare D0 and D10 in Figure 4 ). After metronidazole removal, exposure to siponimod for 3 days (Figure 4 , Siponimod R3) resulted in a dramatic increase in myelinated internodes by comparison with spontaneous remyelination (Figure 4 , Control R3). At R8, the extent of myelinated fibers was back to the level prior to demyelination (Figure 4 , D0, Siponimod R8, and control R8. EM examination of tadpoles following 6 days of recovery confirmed a partial remyelination of metronidazole-induced demyelinated axons (Supplementary Figure S2C) , in agreement with the return to nearly normal level of the number of GFP+ cells. Evaluation of the g-ratios representing myelin thickness with respect to axon diameter revealed a reduction in myelin thickness, suggestive of remyelination, in siponimod remyelinated animals (g = 0.85 ± 0.04) versus controls not subjected to demyelination (g = 0.82 ± 0.04, p < 0.001) (Supplementary Figure S2D) .
The promyelinating effect of siponimod is mediated through S1PR5
Siponimod is a potent and selective agonist of S1P receptors with an EC50 of 0.39 nM for S1P1 and 0.98 nM for S1P5 receptors, respectively. 29 We questioned which receptor implicated the promyelinating effect of siponimod. As remyelination was observed with the selective Dashed line represents control value set as 1 (n = 6 tadpoles per condition, from at least two independent experiments. Parametric two-way ANOVA (after normality test passed using Shapiro-Wilk normality test) followed by an uncorrected Fisher's LSD test *p < 0.05; **p < 0.01; ***p < 0.001. S1PR5 agonist (UC-42-WP04), but not with the selective S1PR1 agonist (AUY954), we favored the possibility that siponimod induced remyelination through S1PR5. If this were the case, siponimod should lose efficiency after S1P5 receptor deletion. We took advantage of the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system (Crispr/Cas9) to test this hypothesis. 30 To determine the exact mutations of s1pr5-S and s1pr5-L, the genomic DNA from 6 F0 embryos, identified after the T7 endonuclease-based mutation detection, was extracted and sequenced. Each embryo presented different degrees of deletion (between 2 and 169 bp) leading to shift of the reading frame and premature STOP codon, for both s1pr5-L and s1pr5-S genes ( Figure 5(a) ). Each of these embryos at stage 55 was submitted to metronidazole demyelination and treated with siponimod. The pro-remyelinating effect of siponimod was no longer observed in the S1PR5 −/− embryos ( Figure 5(b) ).
To confirm oligodendroglial S1P5 receptor loss, mutated tadpoles were euthanized after the demyelination-remyelination experiments, and immunolabeled with anti-S1PR5 antibodies on brain stem sections. As illustrated ( Figure 5(c) ), S1PR5 protein was not immuno-detectable in GFP+ cells in any of the six MBP-GFP-NTR; s1pr5 −/− tadpoles examined.
Discussion
For the past 15-20 years, significant therapeutic progress has resulted from developing anti-inflammatory strategies in MS. These treatments are efficient in diminishing numbers of relapses, but their influence on long-term disability is unclear. Loss of the myelin sheath perturbs normal axon functioning and persistent demyelination renders them vulnerable to irreversible damage leading to axonal transection, with consequent disability accumulation. Spontaneous remyelination can occur, but most often endogenous repair mechanisms are insufficient, notably during aging. The experimental demonstration that environmental clues can restore remyelination potential of aging OPCs indicates that pharmacological approaches may be developed to restore, increase, or accelerate remyelination. 31 Several groups have recently developed in vitro screening approaches for small molecules that drive OPC differentiation. 13, 16, 17 These in vitro high-throughput screens can identify hit molecule candidates to be further validated in in vivo experimental models of demyelination.
Rodents are the preferred animal models, with primary demyelination induced either by detergents to disorganize the myelin sheath (e.g. lysolecithin) or by killing oligodendrocytes with toxins (such as cuprizone or ethidium bromide). In other models, demyelination is secondary to an autoimmune attack as in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE). 32 Toxin-induced models of demyelination do not mimick MS, but they allow the fundamental biology of remyelination to be explored without the confounding and complicating involvement of an autoimmune process. 33 Although rodents may be considered as the "standard" experimental model to investigate demyelination and remyelination, they are costly, time-consuming, and not ideal for longitudinal investigation in the same animal. Although the last decade has seen considerable progress for in vivo imaging of live cells in the normal and demyelinated CNS, 34 technical issues strongly limit imaging in deep layers of mouse brain, such as myelinated axonal tracts. Tadpole transparency allowed us to overcome these limitations by using transgenic Xenopus expressing fluorescent reporter and a suicide protein in oligodendrocytes.
We present results on 20 molecules previously described, usually in vitro, as candidates to promote remyelination.
The Xenopus results are in good agreement with reports on promyelinating efficacy of clemastine, 16 benztropine, 13 and retinoic acid 24 in mammalian cells. A recent small size Phase II study of clemastine in chronic optic neuritis showed some positive results. Concerning siponimod, no data on remyelination are reported, but a recently completed Phase III study showed some positive results in secondary-progressive MS. 5 Fingolimod (acting on S1PR1, S1PR2, S1PR3, and S1PR5, and which is used in the clinic) also promoted remyelination, a finding in agreement with previous data in culture. 19 In contrast, clobetasol and miconasole, known to be efficient remyelinating candidates in vitro as well as in vivo in the mouse, 17 were without effect in the Xenopus model. One possible explanation is that these molecules were screened for their ability to generate new oligodendrocytes, while in the MBP-GFP-NTR Xenopus model, there is no need to generate new OPCs since remyelination results from maturing OPCs (Sox10+ cells) already present in the optic nerve prior to demyelination, without requiring additional production of OPCs. 35 Generation of new oligodendrocytes is only one possible mechanism to favor remyelination. It has been described that OPCs are present in some chronic lesions of MS, so remyelination is limited not only by an absence of precursors or their failure to generate oligodendrocytes but by the defective maturation of OPCs. 36 However, an advantage of Xenopus as opposed to other aquatic models, lies in myelin biology and the fundamental difference in the molecular composition of myelin between teleosts and tetrapods. Teleosts, and zebrafish in particular, use P0 as major myelin protein both in the CNS and in the peripheral nervous system (PNS). In contrast, starting with amphibians (including Xenopus), a dramatic evolutionary change in myelin composition between PNS and CNS occurred. In tetrapods (including amphibians and mammals), the major myelin protein in the PNS remains P0, while in the CNS, it is PLP and MBP. This event occurred in amphibians and has been maintained throughout evolution up to mammals, including humans.
An advantage of the Xenopus model is read-out rapidity: after 10 days of demyelination, remyelination effects were seen by 3 days recovery (hence a total of 13 days), while the cuprizone model in rodent requires at least 6 weeks for demyelination and an additional 3 weeks for recovery. A final advantage of the Xenopus model is that assessing demyelination and remyelination is performed on the same animals and does not require immunohistochemistry. Although the Xenopus model, as described, is more indicated as a medium throughput screen, it has the potential to be automatized for high-throughput screens. Live imaging of remyelination (automated counting of GFP+ cells) is theoretically possible through the modification of existing automated devices such as the VAST (Vertebrate Automated Screening Technology; Union Biometrica). This device allows the automated pumping from multiwell plates and automated imaging at cellular level of whole zebrafish embryos. This system is limited by the valve and motor pin diameter, which has a maximum of 700 μm diameter. To be transposable to Xenopus tadpoles would require adapting the technology by using larger size capillaries. Overall, the procedure is far more efficient when compared with the efforts, time, and cost necessary to perform the same type of experiment in mice. However, while ideal for screening small molecules, a limit of the MBP-GFP-NTR Xenopus model is that it is not designed to test antibodies, such as anti-Lingo, which would require to be injected into the tadpole and not simply added to the swimming water. Another limitation is that the Xenopus tadpole model may not be adapted to screen drugs aimed at overcoming the decline in remyelination that occurs with advancing age particularly for long-term demyelinating diseases such as MS.
In addition to the rapidity with which the test can be performed, another appreciable advantage of the Xenopus model is using Crispr/Cas9 technology so the molecular mechanism of a given compound can be dissected, with ease and precision. 30 In the case of siponimod, not only S1P5 receptor was directly deleted in the MBP-GFP-NTR-lineage, but the effect of the deletion was tested on six different knock-out (KO) animals. Three arguments strongly support that the remyelinating potency of siponimod is mediated through the S1P5 receptor: first, another S1PR5 agonist improved remyelination; second, in the absence of S1PR5 siponimod was no longer active; and, third, a S1PR1 agonist was inefficient. We did not attempt to delete S1P1 because it is established that within endothelial cells this receptor is required for the coverage of vessels by vascular smooth muscle cells 37 and lethality occurs in embryos of S1P1 receptor-deficient mice, due to rupture of the unreinforced vessels. 38, 39 However, although unlikely, we cannot definitively exclude that some of the benefit from siponimod could be from its potential to act through a different mechanism than a S1PR5 agonist.
A recently completed Phase III randomized, controlled study of siponimod in secondary-progressive MS has met its primary endpoint, compared with placebo. 5 Obinata and coworkers have reported the genetic variations of the s1pr1 coding region from exon sequencing of about 12,000 individuals and their functional consequences, suggesting that individual genetic variations of s1pr1 can influence receptor function and, therefore, infer differential interaction with S1PR1-targeted therapeutics. 37 Concerning s1pr5, deletion of s1pr5 has no apparent evident clinical phenotype in either mouse or Xenopus.
Whether patients with s1pr5 mutation or deletions may differ in their remyelination capacity, disease severity and/or response to siponimod is an as yet unexplored hypothesis.
